A phase II, open-label, multinational, multi-centre, sequential group, dose-escalation study to assess the safety and antiviral activity of LB80380 for 24 weeks in patients with chronic hepatitis B who have developed lamivudine-resistant (YMDD mutant) HBV


Grant Data
Project Title
A phase II, open-label, multinational, multi-centre, sequential group, dose-escalation study to assess the safety and antiviral activity of LB80380 for 24 weeks in patients with chronic hepatitis B who have developed lamivudine-resistant (YMDD mutant) HBV
Principal Investigator
Professor Lai, Ching Lung   (Principal investigator)
Co-Investigator(s)
Professor Yuen Richard Man Fung   (Co-Investigator)
Duration
33
Start Date
2004-05-20
Completion Date
2007-02-19
Amount
678715
Conference Title
Presentation Title
Keywords
Chronic Hepatitis B
Discipline
Gastroenterology/Hepatobiliary
Sponsor
Other projects
Grant Type
LG Life Sciences, Ltd. - General Award
Funding Year
2003/2004
Status
Completed